John Paul SanGiovanni, Sc.D.

Area:

Website:

Google:

Bio:

(196* -- Present)
John Paul SanGiovanni, Sc.D. is a scientist and science administrator whose career has been dedicated to identifying, testing, and evaluating nutrient-based therapies for diseases with cardinal neurodegenerative and angiogenic features. He has worked in senior positions to guide planning, implementation, monitoring and analysis of large-scale multi-center NIH-funded phase III clinical trials (AREDS and AREDS2) that have resulted in development of standard-of-care treatments for age-related macular degeneration (PreserVision AREDS2® series). He is currently a visiting scientist at NIH and Adjunct Associate Professor at Georgetown University School of Medicine where he is applying an integrative omics approach to the study of conditionally essential brain-resident nutrients in their capacity to affect brain and retinal cellular signaling systems – systems known to act in atrophic and neovascular retinal diseases, substance use disorders, and schizophrenia. Dr. SanGiovanni has worked continuously in the field of retinal and brain science for over 30 years, holding positions at the Harvard Medical School (11.5 years), the International Nutrition Foundation (2 years), and The National Institutes of Health (17 years).

In his tenure at the National Eye Institute (2000-2014), Dr. SanGiovanni focused on leading analytic teams and served in a central leadership role as Project Officer of two 5-year, 4500-person, multi-center clinical trials funded at over $25M each. In this capacity he acted with the PI and Study Chair at the highest level of leadership, while acquiring expertise in all aspects of clinical trials. Dr. SanGiovanni served as a key member of the AREDS and AREDS2 Operations Committees for 13 years: 1) conducting and publishing analyses on AREDS data and model systems to identify compounds tested in AREDS2 (these were brought to market by Bausch & Lomb as the AREDS2 PreserVision® series); 2) selecting advisory boards, the study coordinating center, the drug distribution center, the phenotyping center and the 80+ clinical sites for AREDS2; 3) overseeing negotiations with, and monitoring activities for, the AREDS & AREDS2 data coordinating center, the AREDS & AREDS2 photographic reading center, the AREDS2 drug distribution center, 11 AREDS clinical sites and 80+ AREDS2 sites; and, 4) acting as a scientific advisor to the NIH on the active agents used in the AREDS and AREDS2 and writing overviews for prominent journals and medical textbooks. At the time of this writing, a search in PubMed on the term ‘AREDS’ returned 282 publications – over 40 of these were co-authored by the AREDS team. A search on the term ‘AREDS2’ yielded 58 publications, 14 of which are composed by the AREDS2 team. During his time at the NIH, Dr. SanGiovanni published in Science (cover feature), Nature Medicine (cover feature), Science Translational Medicine (cover feature), JAMA, JAMA Ophthalmology, JAMA Oncology, PNAS, J. Neurosci., Pediatrics, and American Journal of Clinical Nutrition. As of January 2018, he has > 60 peer-reviewed publications, 14,000 citations, an i10-Index of 50 and an h-Index of 36.

Dr. SanGiovanni received the NIH Director's Award from Dr. Elias Zehouni in 2008 and Dr. Francis Collins in 2011 for his roles in large-scale genomics projects. He received the Early Career Award from the International Society for the Study of Fatty Acids and Lipids (ISSFAL) in 2010 and was a finalist for the Sigma Xi Young Investigator Award the year before. He has served on technical expert panels for AHRQ and NCCAM.

Dr. SanGiovanni received his doctorate (Sc.D.) from the Harvard School of Public Health – his dissertation was focused on diseases of the CNS that manifest as neural cell loss and pathologic angiogenesis (a vascular anomaly that also supports tumor viability). He trained as a scholar and researcher in clinical trials, neuroscience, perinatology, visual psychophysics, nutritional biochemistry, biostatistics, and epidemiologic research design at Harvard University, Brandeis University, and Boston College. Dr. SanGiovanni is a native English speaker and has good working knowledge of three languages: French, Italian, and Spanish.
(Show less)

Mean distance: 53433

Cross-listing: Nutrition Tree - PHTree